Online edition of India's National Newspaper
Friday, Apr 02, 2004

About Us
Contact Us
Business
News: Front Page | National | Tamil Nadu | Andhra Pradesh | Karnataka | Kerala | New Delhi | Other States | International | Opinion | Business | Sport | Miscellaneous |
Advts:
Classifieds | Employment | Obituary |

Business - Briefly Printer Friendly Page   Send this Article to a Friend

Orchid JV's achievement

CHENNAI: Orchid Chemicals and Pharmaceuticals Ltd. (Orchid) on Thursday announced that its U.S. discovery joint venture, Bexel Pharmaceuticals Inc., that has been working on a novel anti-diabetic molecule (BLX-1002), has successfully completed phase 1(a) clinical trials (double-blinded placebo controlled) and moved the molecule into phase 1(b) clinical trials in Europe. The company has also been granted the certificate of suitability (CoS) by the European Directorate for the Quality of Medicines (EDQM) for its API product Cefadroxil Monohydrate.

Our Bureau

Printer friendly page  
Send this article to Friends by E-Mail

Business

News: Front Page | National | Tamil Nadu | Andhra Pradesh | Karnataka | Kerala | New Delhi | Other States | International | Opinion | Business | Sport | Miscellaneous |
Advts:
Classifieds | Employment | Obituary | Updates: Breaking News |


News Update


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | Home |

Copyright 2004, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu